IRLAB Therapeutics (Q3 review): Approaching study initiation - Redeye

Redeye provides a research update following IRLAB's recent Q3 report. While the company reported revenues and a cash position above our estimates, the report did not include any major surprises. We argue that IRLAB's primary focus ahead will be to carry out the upcoming proof-of-concept study with IRL757 and continue its business development efforts regarding mesdopetam and pirepemat.

Länk till analysen i sin helhet: https://www.redeye.se/research/1134177/irlab-therapeutics-q3-review-approaching-study-initiation?utm_source=finwire&utm_medium=RSS